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Background: Integrated Treatment (IT) has proved effective in treating patients with Substance Use Disorders
(SUD) co-occurring with severe Mental Disorders (MD), less is known about the effectiveness of IT for patients with
SUD co-occurring with less severe MD.
The aim of this study was to investigate the effectiveness of IT for patients with SUD co-occurring with anxiety
and/or depression on the following parameters:
1. The use of substances, as measured by the Alcohol Use Identification Test (AUDIT), the Drug Use Identification
Test (DUDIT), and the Addiction Severity Index (EuropASI).
2. The severity of psychiatric symptoms, as measured by the Symptom Check List 90 r (SCL 90R).
3. The client’s motivation for changing his/her substance use behaviour, as measured by the Substance Abuse
Treatment Scale (SATSr).
Methods: This is a group randomized clinical trial comparing the effectiveness of IT to treatment as usual in
Community Mental Health Centres (CMHCs). Five CMHCs were drawn to the Intervention Group (IG) and four
CMHCs to the Control Group (CG). The allocation to treatment conditions was not blinded. New referrals were
screened with the AUDIT and the DUDIT. Those who scored above the cut-off level of these instruments were
assessed with the Structured Clinical Interview for DSM-IV 1 and 2. We included patients with anxiety and/or
depression together with one or more SUDs.
Results: We included 55 patients in the IG and 21 in the CG. A linear multilevel model was used. Both groups
reduced their alcohol and substance use during the trial, while there was no change in psychiatric symptoms in
either group. However, the IG had a greater increase in motivation for substance use treatment after 12 months
than had the CG with an estimate of 1.76, p = 0.043, CI95% (0.08; 3.44) (adjusted analyses). There were no adverse
events.
Conclusions: Integrated treatment is effective in increasing the motivation for treatment amongst patients with
anxiety and/or depression together with SUD in outpatient clinics.
Trial registration: ClinicalTrials.gov: NCT00447733.
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Substance use disorders (SUD) are among the most com-
mon mental disorders (MD) with lifetime prevalence be-
tween 15 and 27% [1-3]. A high comorbidity between MD
and SUD is established from numerous studies [1,4-7].
This comorbidity is associated with poorer effect of treat-
ment resulting in poorer psychosocial functioning, a
higher number of days in treatment, higher attrition from
treatment, more admissions, and a higher burden of dis-
ease from both their MD and SUD [8-14]. By SUD we
refer to abuse and dependence of both alcohol and illegal
substances.
One of the difficulties in treating this comorbidity is
that treatment services may lack sufficient combined
expertise to treat both types of disorders [15]. This has
often resulted in sequential or parallel treatment ap-
proaches, which tend to result in poor treatment out-
comes, [12,16-18]. To overcome these difficulties, the
Integrated Treatment (IT) approach was developed in
the United States at the end of the 1980’s [18,19] and
clinical guidelines to this treatment were later described
by Minkoff [20]. The main purpose of this approach is
to offer the patient a combined treatment for both the MD
and the SUD by the same therapist or therapeutic team, at
the same site at the same time. This treatment should be
comprehensive, assertive, focusing on both rehabilitation
and harm-reduction, having a long-term perspective and
use multiple, evidence based therapeutic modalities like
Motivational Interviewing (MI) [21-23] and Cognitive Be-
havioural Therapy (CBT) [24,25]. Most clinical guidelines
for the treatment of comorbid MD and SUD are recom-
mending a combination of MI and CBT [26-29].
However, most of the research on the effectiveness of IT
has been conducted on patients with SUD co-occurring
with severe mental disorders. Less is known about the ef-
fectiveness of IT for patients with SUD co-occurring with
less severe mental illnesses such as anxiety and affective
disorders without psychosis. The aim of this study was to
investigate the effectiveness of IT for patients with SUD
together with anxiety and/or depression in psychiatric
outpatient clinics on the following parameters:
1) The use of alcohol and other substances.
2) The severity of psychiatric symptoms.
3) The client’s motivation for changing his/her
substance use behaviour.
Methods
Design
The study compares the effectiveness of Integrated Treat-
ment (IT) to treatment as usual (TAU) in the psychiatric
outpatient clinics of Community Mental Health Centres
(CMHCs). To obtain external validity, we chose a prag-
matic randomized controlled trial (RCT) design. In orderto acquire the calculated sample-size, we chose to run a
multi-centre study. As contamination of knowledge be-
tween therapists and patients between groups was an
obvious risk, we decided to randomize on centre-level.
Blinding was judged impossible and therefore the alloca-
tion to treatment conditions was open at inclusion. Five
CMHCs were drawn to the intervention group and four
CMHCs to the control group. For more details see a pre-
vious paper [30].Participants
Patients were sampled from psychiatric outpatient clinics
at 9 CMHCs located in the south, eastern and central
Norwegian Regional Health Trusts. The CMHCs are part
of the specialist level treatment services located in both
urban and rural parts of Norway. The patients are gener-
ally referred by general practitioners, emergency rooms
and inpatient hospital departments for outpatient special-
ist psychiatric treatment and follow-up. People with anx-
iety and depression are predominantly referred by their
general practitioners.
The inclusion criteria were: new referrals, above 18 years
of age, anxiety disorder and/or depression with or without
a personality disorder together with a disorder of abuse or
dependence from drugs or alcohol. The exclusion criteria
were: psychotic disorder, except episodic drug induced
psychosis, planning to move away from the catchment
area during the 12 months duration of the trial, not able
to speak or read Norwegian, disorder of abuse/depend-
ence of benzodiazepines or nicotine as the only substance
use disorder and acute illness that required immediate
treatment. Those who had an acute illness could be in-
cluded in the trial after receiving the acute intervention if
they were referred back to the outpatient clinic for regular
treatment. Participants who provided informed consent to
participate and completed the baseline assessments were
included in the study.Sample size
At the time of planning the study there were no pub-
lished effect-sizes available from studies comparing the
effects of IT with TAU. We therefore computed a within-
group effect-size based on changes from baseline to
follow-up in the absence of a control group in a treatment
study evaluating the effects of comprehensive individual
and group treatment [31]. The effect-size in this study was
modest (0.57), but with a 5% alpha level and 80% power,
the minimum number to treat was 78 patients (i.e., N = 36
in each group). With 90% power the number was 108 pa-
tients. We expected between 20 and 30 percent dropout
for this group of patients from treatment and assessments,
and therefore planned to include a total of 150 patients in
the study.
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In both groups the therapists were expected to provide
evidence based treatment for the psychiatric disorder of
the patient, including psychopharmacological treatment.
The use of such medications was therefore not a focus
of the study.
The specific background and work-experience of the
therapists in this study was not recorded. Generally, the
therapists at CMHCs come from different backgrounds;
psychologists and medical doctors in addition to nurses
and social workers specialising in psychotherapy.
In the intervention group, three to five therapists at
each CMHC and their local trial administrators received
training in IT. This consisted of 35 hours of training in
Motivational Interviewing (MI), Cognitive Behavioural
Therapy (CBT), involving families and advice on pharma-
cological treatment. The training was repeated after 6 and
12 months. The local trial administrators and therapists
were encouraged to have regular peer-group meetings at
their CMHC. The investigators had regular contact with
the local trial administrators by phone, e-mails and visits
at the CMHCs for support.
The patients in the intervention group received IT for
both their psychiatric disorder and their substance use
disorder (SUD). The IT consisted of the treatment mo-
dalities CBT and MI. In addition, the therapists were to
involve the patient’s family and have a more active atti-
tude towards the patient in regard to getting the patient
into treatment and continuing treatment, for example by
calling or visiting the patient on “no show”. The services
should also be comprehensive, i.e. that the services should
be directed against a broad array of areas of functioning
that are frequently impaired in clients with co-occurring
mental and SUD such as housing, vocational functioning,
ability to manage the psychiatric illness and family and so-
cial relationships [25]. The treatment was not manualized
although a descriptive treatment guide was provided.
In the control group, the patients received treatment
as usual (TAU). TAU is a difficult term to define as it
depends greatly on the preference, skills, knowledge and
resources of the therapists delivering it [32]. Commonly,
the treatment methods used in CMHCs include psycho-
dynamic and cognitive therapies used with an eclectic
approach tailored to meet the differential needs of the
individual patient. However, traditionally the treatments
given at psychiatric outpatient clinics have focused mainly
on the psychiatric disorders, and given little attention to
the SUD.
Procedures
We trained and paid one therapist at each CMHC to ad-
minister the project locally. These local trial administra-
tors had 3 days of training on how to run the project
and the instruments used for screening and assessments.Their scoring of case-vignettes with the EuropASI, chap-
ter E, [33,34] was evaluated by a certified teacher. The
trial administrators assessed all participants at baseline,
6 and 12 months of follow-up, while the initial screening
was conducted by the therapists that the patients were
referred to.
All new referrals to the psychiatric outpatient clinics
of the CMHCs during a defined time period were to be
screened with the Alcohol Use Disorder Identification
Test (AUDIT) [35] and the Drug Use Disorder Identifi-
cation Test (DUDIT) [36] to identify individuals that
may have a problematic use of substances. The cut offs
for the AUDIT were set to 6 for women and 8 for men
[37]. The cut offs for the DUDIT were set to 2 and 6 for
women and men respectively [36]. To be able to meas-
ure change in substance use during the 12 months of
follow-up, the instructions for the AUDIT and the
DUDIT were altered to cover substance use during the
last 6 months instead of the original last 12 months.
New referrals could include patients with a previous
treatment history at the CMHC.
Those who scored above the threshold level on either
of the screening instruments were to be referred to the
local trial administrator for further assessments. Firstly,
the Structured Clinical Interviews for DSM-IV axis 1
and axis 2 disorders (SCID 1 and SCID 2) [38,39] were
used to assess whether the patients fulfilled the inclusion
criteria. The patients that fulfilled the inclusion criteria
without fulfilling any exclusion criteria were included in
the study.
At baseline and both follow up interviews the included
patients were assessed with the Symptom Check List 90
(SCL-90R) [40-42], the European Addiction Severity Index
(EuropASI), chapter E, the Health of the Nation Outcome
Scale (HoNOS) [43,44], the Alcohol Use Scale (AUS), the
Drug Use Scale (DUS) [45,46], the Global Assessment of
Functioning Scale (split version) (GAF) [47,48] and the
Substance Abuse Treatment Scale (SATS-r) [49]. The
assessments with the AUDIT and the DUDIT were re-
peated at 6 and 12 months of follow up. The SCID 1 and
the SCID 2 were conducted at inclusion only.
For more details see a previous article [30].
Outcome measures
To examine the change in the use of substances (alcohol
and illegal drugs) during the course of the trial, we used
the AUDIT and the DUDIT to assess changes during
the last six months and the EuropASI to assess changes
during the last 30 days. The response variables from
the EuropASI were coded in the following way: ASI-
Alcohol = the number of days using alcohol on a regular
basis during the last 30 days (question E1 in the Euro-
pASI manual), ASI-Illegal substances = the number of
days using any illegal substances during the last 30 days
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E12 in the EuropASI manual).
To examine the change in psychiatric symptoms in re-
gard to anxiety and depression during the course of the
trial, we used the sum scores of the SCL-90R anxiety,
depression and general severity indexes.
Integrated Treatment is motivation-based, i.e. adapted
to the patient’s motivation for change. This approach is
based on the Stages of Change [50,51] and the closely
related Stages of Treatment [52]. We therefore examined
how the patient’s motivation for changing substance use
behaviours changed during the trial. To measure this we
used the Substance Abuse Treatment Scale (SATS-r).
The outcome measures were examined on the individ-
ual level.Data analyses
When comparing the background variables of the two
groups the Student’s t-test was used for normally distrib-
uted continuous variables and the Mann-Whitney-U test
was used for skewed continuous variables. The Pearson’s
chi-square test was used for categorical variables. In cases
where one or more cells had an expected count less than
five, the Fisher’s Exact test was used.
To examine whether there were differences between
the two groups in regard to treatment response, we used
a linear multilevel model where the different response
variables were modelled as a function of group and time
and adjusted for covariates. The clustering in the data
was accounted for by a random intercept at patient level
and at centre level. The primary target of analysis was
the interaction between group and time, as this indicates
the different treatment responses between groups during
the course of the trial. We ran both Intention to treat
and Completers analyses.
The intention to treat analyses (ITT) were adjusted with
Age and Gender in addition to the following variables: Liv-
ing alone, Having his/her own apartment, and Having
compulsory school only, as these variables showed a statis-
tically significant difference or at least a 10 percent-point
difference between groups at baseline. We continued with
completers analyses in the same way and adjusted these
with Age and Gender in addition to the following variables:
Being in a relationship, Having his/her own apartment,
Having paid work, and Having compulsory school only or
senior high school as these variables showed a statistically
significant difference or at least a 10 percent-point differ-
ence between the completer groups at baseline. Com-
pleters were defined as having received at least 5 sessions
and having met for at least 1 follow-up interview. The rea-
son for adjusting for variables that had a 10 percent point
difference or more without showing a statistically signifi-
cant difference between groups is that the material issomewhat small and we wanted to make sure to include
all possible confounders.
The residuals were normally distributed for all re-
sponse variables except for the DUDIT and the ASI vari-
able for illegal substances. The analyses were performed
using SPSS version 20.0 [53].Ethics
There was a complete discussion of the study with
potential participants and written informed consent was
obtained after this discussion. The study was approved
by the Regional Committee for Medical and Health
Research Ethics in Norway (REC-East) who approved
and monitored the study, and this approval is in accord-
ance with the Declaration of Helsinki.Results
Flow of centres and participants and protocol deviations
This was a difficult study to conduct and the challenges
we encountered are described in detail in a previous art-
icle [30]. Thirty-five CMHCs from 3 out of 5 Regional
Health Trusts were invited to participate in the trial but
only 9 CMHCs accepted. Two months into the project,
one of the centres in the control group resigned. An-
other centre in the control group did not manage to in-
clude any patients during the time span of the trial,
leaving 5 centres in the intervention group (IG) and two
centres in the control group (CG).
All new referrals were to be screened with the AUDIT
and the DUDIT. However, only 35% of the new referrals
were screened. Eighteen per cent of the screened pa-
tients scored above the cut-off level of the screening in-
struments, and only 31% of these patients were referred
to the local trial administrator for the baseline evaluation
(Figure 1). All these challenges delayed the project and
are thoroughly discussed in a previous paper [30].
The initial recruiting period was from April until
December 2007 and the follow-up period continued one
year after inclusion. As recruitment of patients proved
to be slow, the inclusion period was extended by one
year. In the end only 76 patients, 55 in the IG and 21 in
the CG (ranging from 6 to 16 patients between centres)
were enrolled.
After inclusion, 16 patients in the IG and 4 patients in
the CG received less than 5 sessions and/or never
returned for follow-up interviews. This left 56 com-
pleters (CG: 17, IG: 39) (Figure 1). There was no signifi-
cant difference in the number of completers between
groups (X 2 = 0.80; df = 1; p = 0.374). There was also no
significant difference in the number of sessions (CG:
mean 18.9, SD 13.5; IG: mean 14.5, SD 11.3, student’s T-
test. -1.4; df = 74; p = 0.160) or in the distribution of
sessions received between groups. In both groups the
Intervention Group Control Group
New referrals meeting for 
first session:
5325
IG: 3421
CG: 1904
New referrals, screened 
with AUDIT and DUDIT:
1867
IG: 923
CG: 944
Under cut-off: 628
Blank form: 25
Acute illness: 7
Clinician deemed patient 
“ineligible”: 7
Other:   9
Foreign language, referred for assessment 
only 
Screened patients scored 
above cut-off level:
340
IG: 247            
CG: 93
No oral consent:   145
Acute illness/too ill: 10
Referred to addiction treatm:  2  
Clinician deemed patient not 
eligible: 4
Unknown: 7
Other: 5
Planning to move, referred for assessment 
only 
Patients above cut-off, 
referred for baseline 
evaluation:
105
IG: 74
CG: 31
Not met for/not completed 
evaluation:   8
Exclusion criteria met: 5 
Inclusion criteria not met: 2
Withdrew consent: 1
Included in the study:
81
IG: 58
CG: 23
Withdrew consent:3
Never met for follow-up 
interviews (11) ormet for less 
than 5 treatment sessions (10):
16
Intention to treat N = 55
Completers N = 39
Under cut-off: 788
Blank form: 63 
Acute illness: 0
No oral consent:   30
Referred to addiction treatm:  5
Referred to other treatment: 2  
Treatment started before 
baseline evaluation: 8
Clinician deemed patient not 
eligible: 13  
Other: 4
Foreign language, planning to move, 
referred for assessment only 
Not completed evaluation:   6
Exclusion criteria met: 1  
Inclusion criterianot met: 1
Withdrew consent:2
Never met for follow-up 
interviews  (3) or met for less 
than 5 treatment sessions (3):4
Intention to treat N = 21
Completers N = 17
Figure 1 Flowchart of participants. Flowchart of patients in the Intervention Group (IG) and the Control Group (CG) [54].
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35 (63.6%), CG: 16 (76.2%) (data not shown).
Comparing completers to non-completers, we found
that there were no differences between completers and
non-completers in regard to the amount of substances
used or the severity of psychiatric symptoms at intake as
measured by the outcome measures at baseline (i.e. the
AUDIT, the DUDIT, the EuropASI, and the SCID-90r)
(data not shown).
Baseline demographics
Table 1 shows the baseline demographics and clinical
characteristics between groups in the ITT analyses, i.e.all the included patients. There is a statistically signifi-
cant difference in age between groups; otherwise, there
are no differences between the groups at baseline. About
half the patients are male and have paid work. The ma-
jority of patients are not in a relationship, are living with
someone and have compulsory school only or senior
high school. Regarding their diagnoses, the majority of
patients have an alcohol use disorder and about half the
patients have a personality disorder in addition to their
mood and/or anxiety disorder.
Looking at the baseline demographics and clinical
characteristics amongst the completers, there is a statis-
tically significant difference between groups in regard to
Table 1 Baseline demographics – intention to treat analyses
Intervention groupa Control groupa Statistic (p-value)b
N = 55 N = 21
Background variables
Age 32.3 (1.39) 42.2 (3.08) −2.93 (0.007)
No. of children below 18 years 0.0 0.0 z: -0.366 (0.715)
Gender (male) 28 (50.9) 12 (57.1) 0.24 (0.626)
In relationship (yes)1 18 (32.7) 8 (38.1) 0.20 (0.659)
Living alone (yes) 20 (37.0) 10 (47.6) 0.71 (0.401)
Nationality (Norwegian)2 53 (96.4) 20 (95.2) 0.05 (1.000)c
Having children in pat.’s care 14 (25.5) 4 (19.0) 0.35 (0.764)c
Has his/her own apartment3 44 (80.0) 19 (90.5) 1.18 (0.496)c
Has paid work4 27 (49.1) 10 (47.6) 0.01 (0.909)
Compulsory school only5 16 (29.1) 2 (9.5) 3.22 (0.129)c
Compulsory school only or senior high school5 46 (83.6) 16 (76.2) 0.56 (0.514)c
Diagnoses
Alcohol use disorder 43 (78.2) 17 (81.0) 0.07 (0.791)
Drug use disorder 23 (41.8) 7 (33.3) 0.46 (0.499)
Mood disorder 41 (74.5) 16 (76.2) 0.02 (0,882)
Anxiety disorder 46 (83.6) 16 (76.2) 0.56 (0.514)c
Personality disorder 30 (54.5) 10 (47.6) 0.29 (0.589)
Other mental disorders 3 (5.5) 4 (19.0) 3.36 (0.087)c
The baseline demographics and clinical characteristics between groups in the Intention to Treat analyses.
a“Age” is presented as mean (SD) and “no. of children below 18 years” is presented as median. All other variables are presented as n (%). Valid percentages
are given.
bThe student’s T-test is used for “age” and the Mann-Whitney-U-test is used for “no. of children below 18 years”. For all other variables the χ2-test is used.
cWhere one or more cells have an expected count less than five the 2 sided Fisher’s Exact test is used.
1“In relationship” =married or cohabitant. Not in relationship = unmarried, widow (er), separated or divorced.
2“Non-Norwegian” = Afghan, Swedish or German.
3“Not having his/her own apartment” = living with parents or friends.
4“No paid work” = being provided for, student loan, unemployment benefit, sickness or rehabilitation allowance, disability pension, retirement pension, National
Assistance, other.
5“Education”: Compulsory school (primary and secondary school), Senior high school (upper secondary school), Higher education (college or university).
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pattern of the baseline characteristics of the completer
group is identical with that of the ITT-group (data not
shown).
Summary of the results
From the ITT analyses (Table 2) we see that there is a sta-
tistically significant reduction in the use of alcohol as mea-
sured by the AUDIT in the CG between baseline and
12 months (12 months). However, the additional reduction
of alcohol use in the IG is not statistically significant
(IG*12 m). There is also a statistically significant reduction
in the use of illegal substances as measured by the DUDIT
in the CG between baseline and 12 months (12 months).
Yet, the additional reduction in the IG is not statistically
significant. There is also a statistically significant reduction
in the use of alcohol as measured by the ASI in the CG be-
tween baseline and 6 months (6 months) and between base-
line and 12 months (12 months). However, the additionalreduction in the IG during the same time periods is not sta-
tistically significant. In summary, both groups reduce their
use of alcohol and illegal substances during the 12 month
course of the trial, but the IG does not improve significantly
more than the CG.
Regarding the change in psychiatric symptoms as mea-
sured by the SCL-90r, there are no statistically signifi-
cant changes from baseline during the course of the trial
in either group.
Regarding motivation for treatment, there is a statisti-
cally significant interaction between group and time re-
garding SATS-r (p = 0.003, adjusted, data not shown).
Looking at Table 2, this effect is evident after 12 months
in both the unadjusted and adjusted analyses (IG*12 m).
This means that the IG has a greater increase in motiv-
ation for substance abuse treatment during the 12 month
course of the trial than the CG.
The completer analyses show similar results as the
intention to treat analyses on all parameters. Regarding
Table 2 Treatment response - intention to treat analyses
Response variables Parameter Unadjusted Adjusted
Estimate Sig. 95% CI Estimate Sig. 95% CI
Lower bound Upper bound Lower bound Upper bound
AUDIT 6 months −1.95 0.197 −4.94 1.03 −1.96 0.195 −4.94 1.02
12 months −3.11 0.034 −5.97 −0.25 −3.10 0.034 −5.96 −0.23
IG*6 m −2.72 0.115 −6.10 0.67 −2.63 0.139 −6.12 0.86
IG*12 m −2.26 0.181 −5.59 1.06 −2.18 0.209 −5.61 1.23
DUDIT 6 months −1.36 0.459 −4.99 2.27 −1.30 0.478 −4.92 2.32
12 months −4.50 0.011 −7.97 −1.03 −4.50 0.011 −7.97 −1.04
IG*6 m −0.39 0.942 −13.61 12.83 −1.49 0.819 −17.30 14.32
IG*12 m 0.74 0.891 −12.48 13.96 −0.29 0.964 −16.11 15.52
SCL-90-anxiety 6 months −0.16 0.319 −0.48 0.16 −0.16 0.327 −0.48 0.16
12 months −0.21 0.191 −0.52 0.11 −0.21 0.194 −0.52 0.11
IG*6 m 0.21 0.491 −0.51 0.92 0.20 0.548 −0.58 0.97
IG*12 m 0.12 0.698 −0.60 0.83 0.11 0.744 −0.67 0.88
SCL-90-depres-sion 6 months −0.20 0.347 −0.61 0.22 −0.19 0.374 −0.60 0.23
12 months −0.37 0.074 0.77 0.04 −0.36 0.081 −0.76 0.05
IG*6 m 0.18 0.576 −0.54 0.90 0.32 0.437 −0.60 1.24
IG*12 m 0.11 0.744 −0.61 0.82 0.25 0.546 −0.67 1.16
SCL-90-GSI 6 months −0.19 0.185 −0.47 0.09 −0.18 0.194 −0.46 0.10
12 months −0.16 0.259 −0.43 0.12 −0.15 0.266 −0.43 0.12
IG*6 m 0.26 0.350 −0.35 0.88 0.27 0.400 −0.45 0.99
IG*12 m 0.03 0.911 −0.58 0.64 0.05 0.884 −0.67 0.76
ASI-alcohol 6 months −5.97 0.002 −9.63 −2.31 −5.88 0.002 −9.55 −2.21
12 months −4.10 0.022 −7.62 −0.59 −3.95 0.029 −7.48 −0.42
IG*6 m −0.55 0.787 −4.53 3.44 2.47 0.210 −1.41 6.36
IG*12 m −2.73 0.170 −6.65 1.18 0.12 0.951 −3.67 3.90
ASI-Illegal substan-ces 6 months −5.59 0.141 −13.07 1.88 −5.56 0.143 −13.03 1.90
12 months −6.39 0.091 −13.82 1.04 −6.45 0.088 −13.87 0.97
IG*6 m 10.02 0.368 −15.36 35.39 9.98 0.364 −15.10 35.06
IG*12 m 8.77 0.426 −16.60 34.13 8.86 0.416 −16.22 33.93
SATS-R 6 months 1.42 0.001 0.57 2.27 1.41 0.001 0.56 2.26
12 months 2.10 <0.001 1.27 2.93 2.09 <0.001 1.25 2.92
IG*6 m 1.59 0.070 −0.16 3.35 1.44 0.085 −0.25 3.12
IG*12 m 1.89 0.038 0.14 3.65 1.76 0.043 0.08 3.44
Examining differences between the Intervention Group and the Control Group in regard to treatment response - Intention to treat analyses.
6 months = The change of the Control group between baseline and 6 months.
12 months = The change of the Control group between baseline and 12 months.
IG*6 m = The additional change of the Intervention group between baseline and 6 months compared to the Control Group.
IG*12 m = The additional change of the Intervention group between baseline and 12 months compared to the Control Group.
AUDIT = The Alcohol Use Disorder Identification Test, DUDIT = The Drug Use Disorder Identification Test, SCL-90-Anxiety = The Symptom Check List 90 anxiety sum
score, SCL-90-Depression = The Symptom Check List 90 depression sum score, SCL-90-GSI = The Symptom Check List 90 Global Severity Index sum score,
ASI-Alcohol = The European Addiction Severity Index, number of days using alcohol on a regular basis during the last 30 days, ASI-Illegal substances = The
European Addiction Severity Index, number of days using any illegal substances during the last 30 days, SATS-R = The Substance Abuse Treatment Scale, revised.
Statistical significant values are written in bold types, a 5% alfa-level is used.
A linear multilevel model is used. The different response variables are modelled as a function of group and time. The clustering in the data is accounted for by a
random intercept at patient level and at centre level. The primary target of analysis was the interaction between group and time. The analyses where adjusted for
by the following covariates: Age, Gender, Living alone, Having his/her own apartment and Having compulsory school only. During the adjusted analyses a
non-restricted Log likelihood was used. In the final models, the restricted Log Likelihood was used.
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http://www.biomedcentral.com/1471-244X/14/67motivation for treatment, there is a statistically significant
interaction between group and time regarding SATS-r
(p = 0.008, adjusted, data not shown). Looking at Table 3,
this effect is evident after 12 months in the unadjusted
analyses (IG*12 m) and after 6 and 12 months (IG*6 m,
IG*12 m) in the adjusted analyses.
Adverse events
There were no adverse events related to this project. How-
ever, one patient included in the IG who was assessed as
having a severe SUD and therefore referred to a private
addiction treatment centre after receiving 3 sessions at the
CMHC, died about 8 months later of an overdose at the
private addiction treatment centre between the 6 and
12 month follow-up interviews. He is included in the ITT
analyses and regarded as missing at 12 months.
Discussion
This study compared Integrated Treatment with TAU
amongst patients in psychiatric outpatient-clinics with
anxiety and/or depression together with SUD. Our main
findings are that both groups reduce their use of alcohol
and other substances, and that the motivation for treat-
ment improves significantly more in the intervention
group.
Our first finding is that both treatment groups show a
statistically significant decline in the use of alcohol as
measured by the AUDIT and the EuropASI and in the
use of other substances as measured by the DUDIT.
This could mean that both interventions are effective in
reducing the use of these substances and that it is more
important to receive treatment than which treatment is
received. It may also be an effect of the assessment itself
and thereby blurring experimental contrast [55,56]. On
the other hand, it may also be a result of type 2 statis-
tical error, as our sample size is quite small. A review
from 2009 found a statistically significant reduction in
the use of alcohol and/or other substances with the use
of Integrated Treatment amongst people with SUD and
co-occurring anxiety and/or depression [57] and the use
of integrated depression and alcohol treatment with
CBT as the main modality has shown a greater reduction
in the use of alcohol compared to TAU in patients co-
morbid of depression and alcohol use disorder [58,59].
Our second finding is that neither group experienced
a significant reduction in psychiatric symptoms. However,
the follow-up time of this study was relatively short. A re-
view from 2008 showed that there were improvements in
mental health in the long term when MI was combined
with CBT [26], which means that these changes may ap-
pear later in the course of treatment . It is also possible that
the SCL-90r is not sensitive for small changes, especially in
this small material. The use of integrated depression and
alcohol treatment with CBT as the main modality hasshown a greater improvement compared to TAU in de-
pressive symptoms in patients comorbid of depression
and alcohol use disorder after 3 and 6 months of follow
up [60,61].
Our final finding is that the intervention group im-
proves significantly in the motivation for treatment. This
indicates that Integrated Treatment increases the patients’
motivation to change their addictive behaviours even
though we fail to find an additional reduction in the use of
alcohol and other substances in the IG. The reason may
be that the motivation for change occurs before an actual
change in behaviour which may occur later. Several stud-
ies have shown that interventions including Motivational
Interviewing as one of the therapeutic components have a
positive effect on the patients’ motivation for treatment
and changing addictive behaviours [26,60]. Saunders
found that even a brief motivational intervention of a
1 hour session was more likely to make a positive shift in
the stages of change measure among opiate users at a
methadone clinic than in the control group [62]. A review
from 2008 showed some effectiveness in the reduction of
substance use in the short term when MI was used alone,
and that there were improvements in mental health in the
long term when MI was combined with CBT [26].
This study has several limitations. Firstly, the sample
size is quite small which indicates the possibility of a
type 2 statistical error. This is a common problem in this
type of treatment research as most randomized clinical
trials fail to enrol the target number of patients during
the target amount of time [62,63]. This problem is even
more evident in research involving people with SUD that
commonly present with high attrition rates from both
treatment and clinical trials [64,65]. Looking at a recent
review on integrated psychosocial interventions for pa-
tients presenting with co-occurring anxiety and/or depres-
sion with SUD, all the included studies had small sample
sizes [57]. Secondly, as most new referrals were not
screened we lost many potentially eligible participants.
We have no way of comparing non-responders with re-
sponders. However, we have no indication that there was
a systematic selection of those who were screened and
those who were not. The representativeness of the partici-
pants from the sample of new referrals should therefore
not be compromised. Thirdly, we did not focus on the use
of psychopharmacological treatment during the course of
the trial. If the use of such medications differed between
groups, this would alter the results. However, the thera-
pists of all CMHCs are obliged to deliver evidence based
treatment for each condition including psychopharmaco-
logical treatment. Another limitation is that we did not
have a good measure for treatment fidelity. This means
that we do not know if the patients in the IG actually
received a different treatment than those in the CG. Many
studies have shown challenges in implementing new
Table 3 Treatment response - completers analyses
Response variables Parameter
Unadjusted Adjusted
Estimate Sig. 95% CI Estimate Sig. 95% CI
Lower bound Upper bound Lower bound Upper bound
AUDIT 6 months −2.20 0.141 −5.14 0.74 −2.22 0.137 −5.15 0.72
12 months −3.53 0.017 −6.41 −0.65 −3.53 0.017 −6.41 −0.65
IG*6 m −3.18 0.057 −6.46 0.099 −2.72 0.106 −6.02 0.59
IG*12 m −2.76 0.097 −6.03 0.51 −2.35 0.160 −5.64 0.94
DUDIT 6 months −0.97 0.615 −4.80 2.86 −0.98 0.612 −4.81 2.84
12 months −4.18 0.029 −7.92 −0.43 −4.18 0.029 −7.92 −0.43
IG*6 m 1.51 0.784 −11.80 14.82 −1.45 0.806 −15.87 12.96
IG*12 m 2.49 0.652 −10.82 15.79 −0.48 0.935 −14.89 13.93
SCL-90-anxiety 6 months −0.13 0.418 −0.45 0.19 −0.13 0.429 −0.45 0.19
12 months −0.17 0.289 −0.49 0.15 −0.17 0.285 −0.49 0.15
IG*6 m 0.34 0.230 −0.22 0.89 0.38 0.204 −0.21 0.97
IG*12 m 0.22 0.429 −0.33 0.78 0.27 0.372 −0.33 0.86
SCL-90-depres-sion 6 months −0.20 0.372 −0.63 0.24 −0.19 0.374 −0.63 0.24
12 months −0.36 0.097 −0.80 0.07 −0.37 0.094 −0.80 0.06
IG*6 m 0.27 0.501 −0.66 1.19 0.34 0.393 −0.57 1.25
IG*12 m 0.18 0.646 −0.75 1.11 0.25 0.525 −0.66 1.16
SCL-90-GSI 6 months −0.16 0.257 −0.45 0.12 −0.16 0.260 −0.45 0.12
12 months −0.13 0.353 −0.42 0.15 −0.14 0.345 −0.42 0.15
IG*6 m 0.39 0.200 −0.30 1.09 0.43 0.157 −0.23 1.08
IG*12 m 0.15 0.595 −0.54 0.85 0.18 0.511 −0.48 0.84
ASI-alcohol 6 months −6.28 0.001 −9.96 −2.61 −6.40 0.001 −10.09 −2.72
12 months −4.29 0.020 −7.90 −0.69 −4.29 0.020 −7.91 −0.68
IG*6 m −0.72 0.723 −4.70 3.27 1.86 0.432 −3.56 7.29
IG*12 m −3.40 0.093 −7.38 0.58 −1.05 0.648 −6.44 4.34
ASI-Illegal substances 6 months −5.41 0.182 −13.41 2.58 −5.41 0.182 −13.40 2.58
12 months −6.24 0.125 −14.23 1.76 −6.24 0.125 −14.23 1.76
IG*6 m 10.32 0.315 −13.15 33.79 10.94 0.308 −13.90 35.78
IG*12 m 8.90 0.381 −14.56 32.37 9.55 0.368 −15.28 34.38
SATS-R 6 months 1.65 <0.001 0.81 2.49 1.65 <0.001 0.81 2.49
12 months 2.35 <0.001 1.51 3.19 2.35 <0.001 1.51 3.19
IG*6 m 1.76 0.070 −0.19 3.71 1.63 0.050 0.001 3.25
IG*12 m 2.18 0.034 0.22 4.14 2.07 0.020 0.44 3.70
Examining differences between the Intervention Group and the Control Group in regard to treatment response – Completers analyses.
Completers = Having received at least 5 sessions and met for at least one follow-up session.
6 months = The change of the Control group between baseline and 6 months. 12 months = The change of the Control group between baseline and 12 months.
IG*6 m = The additional change of the Intervention group between baseline and 6 months compared to the Control Group. IG*12 m = The additional change of
the Intervention group between baseline and 12 months compared to the Control Group. AUDIT = The Alcohol Use Disorder Identification Test, DUDIT = The Drug
Use Disorder Identification Test, SCL-90-Anxiety = The Symptom Check List 90 anxiety sum score, SCL-90-Depression = The Symptom Check List 90 depression sum
score, SCL-90-GSI = The Symptom Check List 90 Global Severity Index sum score, ASI-Alcohol = The European Addiction Severity Index, number of days using
alcohol on a regular basis during the last 30 days, ASI-Illegal substances = The European Addiction Severity Index, number of days using any illegal substances
during the last 30 days, SATS-R = The Substance Abuse Treatment Scale, revised.
Statistical significant values are written in bold types, a 5% alfa-level is used.
A linear multilevel model is used. The different response variables are modelled as a function of group and time. The clustering in the data is accounted for by a
random intercept at patient level and at centre level. The primary target of analysis was the interaction between group and time. The analyses where adjusted for
by the following covariates: Age, Gender, Being in a relationship, Having his/her own apartment, Having paid work and Having compulsory school only or senior high
school. During the adjusted analyses a non-restricted Log likelihood was used. In the final models, the restricted Log Likelihood was used.
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cant improvement in motivation for treatment in the IG
which indicates that there was a difference in the interven-
tions given between groups. Further, one could argue that
the trial mainly measures the effectiveness of motivation
as patients were classified as completers if they had met at
as few as five sessions. On the other hand, in both groups
the majority of patients received 10 sessions or more, al-
though such complex conditions might need longer treat-
ment and observation time than the one year follow-up of
this and most other trials. Finally, as this is a group ran-
domized trial consisting of only 7 centres, the results
could be biased if one of the centres would perform much
better or much worse than the other centres. To handle
this potential bias, we have used a random intercept at
centre level in our linear multilevel model.
To judge whether this intervention is cost-effective
given the extra training needed to deliver it, one will
need larger studies and a longer time of follow-up.
Interpretation of results
As we found a decline in substance use in both groups,
common therapeutic factors are demonstrated but it is
unclear whether integrated treatment is more effective
in reducing substance use. This might be explained by
insufficient power. On the other hand, there was a sig-
nificant improvement in motivation for treatment in the
IG which supports that Integrated Treatment is a fruitful
approach when the patient is comorbid with SUD and
psychiatric disorders, not only severe mental disorders,
but also milder conditions dominated by anxiety and de-
pression. However, these findings should be seen as pre-
liminary and confirmed in larger studies before further
conclusions can be drawn.
Generalizability
To provide external validity, we chose a pragmatic RCT
design with wider inclusion criteria and few exclusion
criteria. The results therefore should be generalizable to
the average adult patient population in CMHCs with co-
occurring anxiety and/or depression together with SUD.
This article is to a large extent structured as recom-
mended by the Consort group for reporting on group
RCTs [68-75].
Conclusions
Integrated treatment is effective in increasing the motiv-
ation for treatment amongst patients with anxiety and/
or depression together with SUD in outpatient clinics.
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